NEWS
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights include PrognomiQ's MOSAIC study, which combines proteomics with other molecular data to improve early-stage lung cancer detection, and Salk Institute's research on Relative Energy Deficiency in Sport (REDs) affecting 40% of athletes. The presentations will demonstrate how Seer's technology enables multi-omic research at unprecedented depth, scale, and speed.
Key highlights include PrognomiQ's MOSAIC study, which combines proteomics with other molecular data to improve early-stage lung cancer detection, and Salk Institute's research on Relative Energy Deficiency in Sport (REDs) affecting 40% of athletes. The presentations will demonstrate how Seer's technology enables multi-omic research at unprecedented depth, scale, and speed.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment